Vitamin D3 supplementation shows no therapeutic benefits in severe COVID-19 patients, study finds
By Angela Betsaida B. Laguipo, BSNNov 18 2020
Vitamin D has gained immense popularity amid the coronavirus disease 2019 (COVID-19) pandemic. Several studies have tied vitamin D deficiency to coronavirus infection. Health experts are investigating if taking vitamin D may help protect against severe COVID-19.
A team of researchers at the University of São Paulo in Brazil aimed to determine if vitamin D3 supplementation reduces length of stay in hospitalized patients with severe COVID-19.
Study: Effect of Vitamin D3 Supplementation vs Placebo on Hospital Length of Stay in Patients with Severe COVID-19. Image Credit: Ozornina / Shutterstock
The researchers found that taking vitamin D3 was safe and effective in increasing 25-hydroxyvitamin D levels but did not reduce hospital length of stay or yield any other clinically-relevant outcomes compared with a placebo.
In the current study, which appeared on the preprint server medRxiv*, the team wanted to determine if vitamin D supplementation can reduce the hospital length of stay and improve clinical outcomes in hospitalized COVID-19 patients.
The team conducted a multicenter, double-blind, randomized and placebo-controlled trial in two centers in Sao Paulo, Brazil. The trial included 240 hospitalized patients with severe COVID-19.
The team randomly assigned patients to receive either a single oral dose of 200,000 IU of vitamin D3 or a placebo.
The team wanted to determine the effects of vitamin D3 supplementation on the hospital length of stay, defined as hospital discharge or death. Other recognized outcomes were mortality, mechanical ventilation requirement, admission to the intensive care unit (ICU) and serum levels of 250-hydroxyvitamin D, calcium, creatinine, D-dimer and C-reactive protein.
The team has found that of the 240 randomized patients, vitamin D supplementation markedly increased serum 25-hydroxyvitamin D levels compared to placebo.
The supplement increased the serum vitamin D levels in 86.7 percent of the patients, compared to 11 percent in the placebo group.
- High prevalence of cross-reactive anti-SARS-CoV-2 antibodies in sub-Saharan Africa
- Discovery of novel hidden gene in SARS-CoV-2
- ‘A great day for science and humanity’; Pfizer’s COVID-19 vaccine is found to be 90% effective
"There were no changes in any health-related laboratory markers following the intervention. Vitamin D3 supplementation was well tolerated, and no severe adverse events were reported throughout the trial," the researchers noted.
However, vitamin D3 supplementation is ineffective in improving hospital length of stay or any other clinical outcomes among hospitalized patients with severe COVID-19.
The single dose of 200,000 IU of vitamin D3 supplementation could not promote any clinically relevant effects among the study participants.
"Thus, this trial does not support the use of vitamin D3 supplementation as an adjuvant treatment of patients with COVID-19," the team concluded.
The study has several limitations, however. The sample size was too small to detect significant changes for secondary outcomes. Further, the patients had comorbidities or coexisting diseases and so were using diverse medication regimens which might have impacted the researchers ability to gauge the supplementations efficacy.
Lastly, the proportion of patients with vitamin D deficiency enrolled in the study was lower than those reported in other cohorts.
Vitamin D and COVID-19
A growing body of evidence has shown that vitamin D may enhance innate and adaptive immunity. Vitamin D supplementation could improve macrophages and dendritic cell function, strengthening, and overall immune response.
Inadequate vitamin D levels in the body have been suggested as a possible risk factor for acute respiratory tract diseases, including viral infections. Health experts said that optimal vitamin D levels play an imperative anti-inflammatory role, thereby benefiting COVID-19 patients.
Several studies have explored the potential benefit of vitamin D supplementation on COVID-19 health outcomes.
Observational studies have shown that 25-hydroxyvitamin D levels are linked to better clinical outcomes in respiratory diseases. In one trial, administering boluses of vitamin D3 before the infection was associated with better prognosis and less severe illness among older and frail COVID-19 patients.
The elderly and those with comorbidities are at a higher risk of severe illness and death. Finding potential therapies to avert severe COVID-19 illness is crucial amid the coronavirus pandemic.
Globally, the COVID-19 pandemic has caused over 1.34 million deaths, with more than 55.76 million cases.
medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.